Medpace Holdings, Inc.
MEDP Healthcare Diagnostics & Research
Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.
- Revenue
- +8.50%
- EPS
- +24.6%
- Free cash flow
- −16.6%
Quarter to September 2026, against a year earlier
Follow MEDP
Alert me
Medpace Holdings, Inc. (MEDP) EV/FCF
As of 5 November 2026, Medpace Holdings, Inc. (MEDP) trades at a EV/FCF of 25.7×. Over the past ten years it has ranged from 11.7× (March 2020) to 31.7× (March 2024); the current reading is higher than 93% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 23.2× | 36.47% |
| FY2024 | 17.0× | (27.13%) |
| FY2023 | 23.3× | 20.05% |
| FY2022 | 19.4× | (38.41%) |
| FY2021 | 31.5× | 50.85% |
| FY2020 | 20.9× | 30.37% |
| FY2019 | 16.0× | 13.94% |
| FY2018 | 14.1× | (27.88%) |
| FY2017 | 19.5× | 6.27% |
| FY2016 | 18.4× | 23.51% |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 25.2× | 22.73% |
| Jun 2026 | 20.6× | 11.44% |
| Mar 2026 | 18.4× | (20.46%) |
| Dec 2025 | 23.2× | 9.83% |
| 40 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| GH Guardant Health, Inc. compare | −84.7× |
| ICLR ICON PLC compare | 22.6× |
| DGX Quest Diagnostics Incorporated compare | 23.8× |
| MEDP Medpace Holdings, Inc. | 25.7× |
| QGEN QIAGEN N.V. compare | 25.8× |
| LH Labcorp Holdings Inc. compare | 29.8× |
| ILMN Illumina, Inc. compare | 31.3× |
| RVTY Revvity Inc. compare | 32.6× |
| CRL Charles River Laboratories International, Inc. compare | 43.2× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on MEDP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement